Pennsylvania's HB433 Advances: A Landmark Bill for Breast Health Equity Unanimously Passes the House

 By Lennard M. Goetze, Ed.D – AngioMedical News

 FOR IMMEDIATE RELEASE

In a significant step toward improving breast health care equity in Pennsylvania, House Bill 433 (HB433) passed the Pennsylvania House of Representatives with a resounding 198-5 vote on May 12, 2025. This pivotal legislation, aimed at expanding insurance coverage for diagnostic breast examinations without cost-sharing barriers, represents a victory for patients, advocates, and healthcare providers alike.

Background: The Need for HB433

The origins of HB433 trace back more than a year, when Cheri Ambrose, Founder and President of the Male Breast Cancer Global Alliance, reached out to the Pennsylvania Governor’s office and legislative stakeholders to advocate for improved access to breast imaging services — not just for women, but for all individuals, including men diagnosed with or at risk for breast cancer.

Historically, state insurance mandates have focused on screening mammograms, often leaving significant gaps in coverage for diagnostic follow-ups like MRIs, ultrasounds, and diagnostic mammograms when abnormalities are detected. This has led to financial strain and delayed diagnoses for many patients, particularly men with breast cancer, a group frequently overlooked in traditional breast health policy.

Recognizing this, the House Democratic Insurance Committee began work on HB433, designed to ensure that both screening and diagnostic breast imaging would be accessible without burdensome out-of-pocket costs — a move aligned with updated guidelines from the U.S. Health Resources & Services Administration (HRSA) and federal health insurance mandates set to take effect in 2026.

The Legislative Process: Stakeholder Collaboration and Amendment

On March 26, 2025, Joseph Keller, Senior Research Analyst for the House Democratic Insurance Committee, formally reached out to stakeholders for feedback on both the bill and a proposed amendment (A00204). This amendment refined HB433’s language to enhance its inclusivity and legal precision. Key changes included:

• Replacing gendered language: Substituting “women” with “individuals” to ensure breast health coverage for all, regardless of gender.

• Clarifying insurance applicability: Modernizing outdated legal references and definitions within Pennsylvania’s mammogram law.

• Defining covered costs: Clearly stating that “all costs” would include copayments, coinsurance, and deductibles — with exceptions for certain high-deductible health plans tied to Health Savings Accounts.

• Aligning with HRSA guidelines: Ensuring diagnostic breast examinations would include MRIs, ultrasounds, or diagnostic mammograms for any suspected abnormalities detected in initial screenings.

Cheri Ambrose remained an engaged advocate throughout the process, communicating regularly with Keller and other House staff to monitor progress. After a successful committee adoption of the amendment in April 2025, the bill was scheduled for a final House vote in May.

Final Passage and What Comes Next
On May 12, 2025, the Pennsylvania House of Representatives Led by House Speaker Rep. Joanna McClinton amended the historical act of May 17, 1921 (P.L.0682, No.0284), known as the "Insurance Company Law Of 1921. The house voted overwhelmingly in favor of HB433. Cheri Ambrose received confirmation of the vote directly from Joseph Keller, who expressed appreciation for the ongoing advocacy and stakeholder input that helped shape the bill’s passage. The bill now moves to the Pennsylvania Senate for further consideration. If approved there, it will proceed to the Governor’s desk for final enactment. “No one should have to go into debt to access the health care they need, but high out-of-pocket costs can discourage people from seeking care", states Rep. McClinton. By passing HB 433 this week, the state House took action to help more Pennsylvania men and women access diagnostic breast imaging which can save lives and reduce the overall costs to our state’s healthcare system.”

(L-Image) Representative Gina H. Curry - PA General Assembly also shared her statement about the recent historical legislative amendment. “Breast cancer does not discriminate, and neither should access to care. Men get breast cancer too, fathers, brothers, sons, yet many delay care due to stigma or cost. HB 433 ensures that if you find a lump, you can get answers no matter your gender, zip code, or bank account. Black and Hispanic women are more likely to be diagnosed at later stages and have higher mortality rates. Black women are 2.7 times more likely to face triple negative breast cancer and 28 percent more likely to die from it. This bill tears down the financial walls that keep people from getting the diagnostic tests they need. We are not just saving women’s lives, we are saving lives, period. Because cancer does not wait, and neither should we."

What This Means for the Public

For the public — particularly those affected by or at risk for breast cancer — HB433 represents a monumental step forward. Should it become law, Pennsylvanians will no longer face the burden of out-of-pocket costs for essential diagnostic breast exams if abnormalities are detected during initial screenings. This legislation ensures insurance plans offered, issued, or renewed in the Commonwealth will cover these vital services, aligning state law with evolving federal preventive care standards.

Importantly, by adopting gender-neutral language and including men within the framework of breast health care policy, HB433 acknowledges the realities faced by male breast cancer patients, a demographic long overshadowed in public health conversations.

Conclusion

HB433’s progress exemplifies the power of advocacy, stakeholder collaboration, and responsive legislation. As Pennsylvania moves one step closer to codifying these protections into law, advocates like Cheri Ambrose and legislative champions within the House Insurance Committee offer a clear reminder of what dedicated, patient-centered policy work can accomplish.

For more information about the MALE BREAST CANCER GLOBAL ALLIANCE PREDISPOSITION TESTING PROGRAM, contact us at: www.mbcglobalalliance.org or contact our hotline at: 516.522-0777

Hi Cheri- I wanted to thank you for what you've done in Pennsylvania for male breast cancer. This article echoes what I've been saying since my diagnosis. The BRCA gene mutation test has now been available for 25 years, but until my diagnosis, not one primary caregiver ever suggested I get the simple screening. This, in spite of their knowledge of the breast cancer devastation on my mom's side of the family. They ALL knew. If I was screened, I could have caught my cancer at Stage 1 or even Stage 0. But I was Stage 2 with about the most aggressive tumor one can have; a Ki67 score of 36!!  Nine out of 10 cousins on my mom's side of the family have tested positive for the BRCA2 mutation. Breast cancer took my grandmother, along with my mom and both of her sisters. One of my male cousins passed it on to his daughter. The BRCA2 mutation is "gender neutral," and the Pink Brigade ignores this, while men are passing the mutation to their daughters & sons! That's simple negligence. I'll be clean for 3 years this October 3, but I'm not "clear." The BRCA2 mutation is still there and can trigger new cancer in several places, like the liver & pancreas, the latter being a quick death sentence. So I continue to take daily adjuvants (tumor inhibitors) with all of the attendant side effects and keep my fingers crossed. Fortunately, I have new inhibitor meds my grandmother, mom & aunts never had. Please keep up your good work. I'm constantly beating the drum, too. I've been absent from the Facebook group, as there is a lot going on. But I'll make a point to get in there. I have updates to post on several drugs I'm on. All the best, Mark Larsen, Tampa Bay, FL

---------------------------------------------------------------------------------------------------------------------------------------------------

THIS MESSAGE IS BROUGHT TO YOU BY THE MALE BREAST CANCER GLOBAL ALLIANCE

The Male Breast Cancer Global Alliance (MBCGA) is leading the charge in awareness, education, and support for men affected by this disease. This organization has built a worldwide network of survivors, advocates, researchers, and healthcare professionals working to shatter the stigma and silence surrounding male breast cancer. They’ve played a crucial role in pushing for more inclusive research, advancing public health messaging, and ensuring men have access to the resources they need. Through tireless advocacy and collaboration, MBCGA has helped get male breast cancer recognized in global cancer policy and has elevated the voices of countless survivors. Their data-driven campaigns and survivor-led storytelling have reached millions, and their partnership with Bard Diagnostics is all about scaling that impact through accessible genetic testing.

 

RELATED RESOURCES

Under a dedicated partnership with the Male Breast Cancer Global Alliance, BARDDIAGNOSTICS established key programs including: EARLIER DETECTION, PREDISPOSITION GENE TESTING, FIGHT RECURRENCE, ACTIVE SURVEILLANCE AND THE 2ND OPINION SCAN. For the many MEN who seek a significantly improved lifestyle or an upgrade in personalized healthcare, getting better answers about your state of health is paramount and IT ALL STARTS WITH STATE OF THE ART DIAGNOSTICS. The visionary paradigm that makes up true personalized medical care involves the integration between modalities, a collaboration between specialists and an upgrade in their strategic approach and you'll find it all at BardDiagnostics. 

UNCOVERED – Shedding Light on Male Breast Cancer
The first official newsletter from the Male Breast Cancer Global Alliance, launched in proud partnership with AngioMedical Media and the Integrative Cancer Resource Society. Rooted in the belief that education is power, UNCOVERED delivers essential news, scientific updates, and survivor stories to inform and inspire. Each issue is packed with the latest in male breast cancer research, treatment innovations, and advocacy efforts from around the globe. Whether you're a patient, caregiver, or medical professional, UNCOVERED is your trusted source for facts and forward-thinking perspectives. Join us in uncovering the truth—and empowering lives through knowledge. (visit our regularly updated Newsletter)

The INTEGRATIVE CANCER RESOURCE SOCIETY is a self-funded (Linkedin Based) independent volunteer group of non-profit foundations/charities, researchers, educators, community leaders and survivors. Under the spirit of collaboration and partnership, we are joined to bring a new level of support to cancer patients, survivors and all those seeking current information about cancer care. We form a unique network of support for one another- while driven to help those who need additional resources, technical updates or empowerment on the road to recovery. ICRS uses the power of the "interweb" to reach a global audience and a network of resources beyond our local borders. We have engaged some of the most impressive minds, perspectives and resources and enjoyed the exchange of vital information that is useful to all. Thanks in part to digital collaboration, these "foreign" connections have always been a part of our cancer crusade, now joining us in what we call "BORDERLESS MEDICINE".

In great support of a the global movement of NON-INVASIVE medicine, we proudly introduce the INTEGRATIVE HEALTH RESEARCH CENTER by AngioInnovation Research (501c3). This New York city-based diagnostic imaging validation lab is established to clinically identify the efficacy, performance and supportive claims set by non-invasive therapeutics and diagnostic solutions. Co-founded by Dr. Robert L. Bard, the IHRC offers a non-profit, non-commercialized testing option for health-related innovations who seek an independent and impartial reporting through single-case pilot studies or IRB-Based clinical trials. The IHRC employs credentialed medical professionals and specialists in clinical research whose experience contributes to the unique strategic approach of each test study. (Visit: the AngioInstitute website)